#### 1 Distinct immune signatures are a potent tool in the clinical management of

#### 2 cytokine-related syndrome during immune checkpoint therapy

3

4 Douglas Daoudlarian<sup>1</sup>, Amandine Segot<sup>2</sup>, Sofiya Latifyan<sup>3</sup>, Robin Bartolini<sup>1</sup>, Victor Joo<sup>1</sup>,

5 Nuria Mederos<sup>3</sup>, Hasna Bouchaab<sup>3</sup>, Rita Demicheli<sup>3</sup>, Karim Abdelhamid<sup>3</sup>, Nabila Ferahta<sup>3</sup>,

6 Jacqueline Doms<sup>1</sup>, Grégoire Stalder<sup>2,4</sup>, Alessandra Noto<sup>1</sup>, Lucrezia Mencarelli<sup>1</sup>, Valérie

7 Mosimann<sup>3</sup>, Dominik Berthold<sup>3</sup>, Athina Stravodimou<sup>3</sup>, Claudio Sartori<sup>5</sup>, Keyvan

8 Shabafrouz<sup>3</sup>, John A Thompson<sup>6</sup>, Yinghong Wang<sup>7</sup>, Solange Peters<sup>3</sup>, Giuseppe Pantaleo<sup>1</sup>,

9 Michel Obeid<sup>1\*</sup>

10

<sup>1</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of

- 12 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne, 13 Switzerland
- <sup>14</sup><sup>2</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
- 15 Oncology, Service and Central Laboratory of Hematology, Rue du Bugnon 46, CH-1011
- 16 Lausanne, Switzerland
- <sup>3</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of

18 Oncology, Medical Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

<sup>4</sup>Service of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-

20 Champsec 86, CH-1951 Sion, Switzerland

<sup>5</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of

22 medicine, internal medicine service, Rue du Bugnon 17, CH-1011 Lausanne, Switzerland

- 23 <sup>6</sup>Department of Medicine, Fred Hutchinson Cancer Research Center, University of
- 24 Washington, Seattle, WA, USA
- <sup>7</sup>Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD
   Anderson Cancer Center, Houston, TX, USA
- 27

#### 28 \*Corresponding author:

- 29 Pr Michel Obeid, MD-PhD
- 30 Lausanne Center for Immuno-Oncology Toxicities LCIT
- Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland
- 32 Centre Hospitalier Universitaire Vaudois (CHUV)
- 33 **Email:** michel.obeid@chuv.ch
- 34
- KEY WORDS: Immune profiling, immune checkpoint inhibitors, cytokine release
   syndrome, sepsis, hemophagocytic lymphohistiocytosis, biomarkers, decision tree.
- 37
- 38
- 39

#### 40 Abstract

Immune-related cytokine release syndrome (irCRS) frequently occurs during immune 41 42 checkpoint inhibitor (ICI) therapy. In the present study, we have attempted to identify 43 biomarkers in oncology patients experiencing irCRS-like symptoms (n=35), including 9 44 patients with hemophagocytic lymphohistiocytosis (irHLH)-like manifestations (8 classified 45 as Grade (G) 4 irCRS and 1 as G3 irCRS) and 8 with sepsis, differentiating between irCRS, 46 irHLH and sepsis. Patients grouped in three clusters based on distinct cytokine profiles and 47 survival outcomes. We identified 24 biomarkers that significantly discriminated between 48 irHLH and irCRS G3 (P < 0.0455 to < 0.0027). Notably, HGF and ferritin demonstrated superior predictive values over the traditional HScore, with a positive predictive value (PPV) 49 and negative predictive value (NPV) of 100%. Furthermore, CXCL9 not only distinguished 50 51 between irHLH and irCRS G3, but was also a predictor of treatment intensification with 52 tocilizumab (TCZ) with a PPV of 90% and a NPV of 100%. Other parameters, such as 53 leukocyte count, neutrophils, ferritin, IL-6, IL-7, EGF, fibrinogen, and GM-CSF, were 54 effective in discriminating sepsis from high-grade irCRS with a PPV of 75-80% and an NPV 55 of 100%. In comparison to sepsis, the frequencies of CXCR5+ or CCR4+ CD8 memory, CD38+ ITM monocytes, and CD62L+ neutrophils were observed to be higher in high-Grade 56 57 irCRS. Of note, TCZ treatment led to complete resolution of clinical symptoms in 12 patients 58 with high-grade irCRS refractory to corticosteroids (CS). These findings demonstrate the 59 power of unique immunologic biomarkers in determining the severity of irCRS, in predicting 60 survival, and distinguishing between high-grade irCRS, irHLH and sepsis. Therefore, these 61 distinct unique signatures are instrumental for the optimal development of personalized 62 clinical and therapeutic management in patients experiencing irCRS patient.

63

64

#### 65 Main

Immune Checkpoint Inhibitors (ICIs) have reshaped the anticancer landscape, showing 66 67 remarkable efficacy across a spectrum of malignancies (1). However, ICIs are frequently 68 associated with immune-related adverse events (irAEs) (2), which encompass a range of 69 immune-mediated toxicities that raise substantial clinical challenges (1, 3). Among these, 70 immune-related cytokine release syndrome (irCRS) is of particular concern due to its 71 potential severity and life-threatening manifestations(4). irCRS is characterized by an acute, 72 systemic inflammatory response, primarily mediated by an extensive release of cytokines. 73 Historically, irCRS was associated with monoclonal antibodies (mAbs) such as rituximab, 74 brentuximab and obinutuzumab and more recently with T-cell-engaging therapies (e.g., 75 bispecific T-cell-engaging (BiTE) single-chain antibodies) and chimeric antigen receptor 76 (CAR) T cells therapies. irCRS is now increasingly observed in the context of ICI therapy (4-77 12). Severe irCRS can lead to multi-organ dysfunction and, in extreme cases, can be fatal 78 (13).

79 The clinical features and laboratory alterations of irCRS itself are not specific and may 80 overlap or coincide with infectious diseases (14). In severe cases, irCRS may present with 81 sepsis-like clinical signs and laboratory changes mimicking sepsis, macrophage activation 82 syndrome or immune-related hemophagocytic lymphohisticytosis (irHLH) (15-17). Importantly, a subgroup of patients treated with CAR-T cells (18) or BITE (19) can develop 83 84 HLH-like features as a severe variant of CRS. In addition, CAR T-cell associated HLH 85 (carHLH) identified as a CRS variant presented cytokine profiles and clinical manifestations 86 like secondary HLH/macrophage activation syndrome (MAS) (18, 20). HLH can present with a wide spectrum of manifestations ranging from isolated biological abnormalities to a severe 87 88 multi-organ clinical syndrome. Distinguishing between irCRS, especially in high grade (15), and sepsis (21) in patients receiving ICI therapy is crucial for effective clinical management. 89

90 An important unanswered dimension in the progression of irCRS is the extent to which the 91 hyperinflammatory response evolves into or coexists with a compensatory anti-inflammatory 92 response syndrome (irCARS) (22-26). This balance between pro- and anti-inflammatory 93 forces is critical to understanding whether a pronounced anti-inflammatory phase could emerge in response to the inflammatory cascade seen in irCRS. The potential transition from 94 95 an overwhelming inflammatory response to a compensatory anti-inflammatory phase could 96 have profound implications for patients' management and treatment outcomes. Furthermore, 97 the possibility that high-grade irCRS may present with (HLH)-like manifestations adds an 98 additional layer of complexity to the diagnosis and management of severe cases. Delineation 99 of this continuum and its potential overlap with HLH-like presentations is essential to 100 optimize therapeutic strategies and clinical outcomes.

101 A variety of grading systems for CRS have been proposed (27-30) with the objective of 102 establishing standardized criteria. However, the current grading systems present several 103 limitations and the diversity of criteria used are at the base of the inconsistency in evaluating 104 of the safety profiles of different therapeutic agents, and the source of clinical misclassification. For instance, the performance of the HScore (31), traditionally used to 105 106 estimate the individual risk of reactive HLH, may not be appropriate in the case of irHLH 107 resulting from ICI-associated irAEs. Improving these grading systems and scores with precise 108 immune measurements offer a promising avenue for refining the accuracy of severity grading 109 and prognostic predictions, with the ultimate goal of rationalizing patient management and 110 improving therapeutic outcomes.

In the present study, we investigated whether immunologic biomarkers can contribute to establishing solid criteria to apply to the clinical grading and classifications of ICI-associated irAES. For these purposes, comprehensive set of 115 biomarkers, including 50 cytokines, chemokines and growth factors and 44 cellular markers were analyzed. Our ultimate

objective was to identify specific biomarkers that can discriminate between the different clinical manifestations of irCRS including irHLH and sepsis, and to predict severity, and patient survival. These findings are expected to facilitate the development of tailored therapeutic interventions.

119

#### 120 Clinical and demographic characteristics of the cohort.

121 Of the 709 identified patients treated with ICI at the Lausanne University Hospital between 122 2020 and the end of 2023, 43 patients presented with clinical and biological presentation of 123 systemic inflammatory response syndrome (SIRS) such as sepsis or irCRS according to ACCP/SCCM Consensus Conference Committee (32, 33) (Supplementary Table 1). Of 124 125 these, 35 patients were included in the final analysis as described in the study flowchart 126 (Supplementary Fig. 1). A subset of 28 patients were diagnosed with grades 1 to 4 of irCRS 127 according to the Lee grading scale (34) and 7 patients were diagnosed with sepsis, 128 microbiologically documented, including 2 cases of viral and 5 of bacterial sepsis. Extensive 129 screening to exclude an infection as the cause of CRS was part of our local standard of care 130 for irCRS (including HLH). Among the 28 patients with irCRS, 12 [43%] were classified as 131 low-G irCRS (G1, G2) and 16 [57%] as high-G irCRS (G3, G4). Of note, 9 out of 28 (32%) 132 met the criteria of reactive HLH according to the criteria (31). The use of five of the eight 133 diagnostic criteria from HLH-2004 (35) has proven to be an effective tool for the diagnosis of 134 irHLH. Adjustments to the HLH-2004 criteria, including setting hyperferritinemia cutoffs at 135  $3000 \ \mu g/L$  and fever at  $38.2^{\circ}C$ , have increased sensitivity and specificity to 97.5% and 136 96.1%, respectively, as recently reported (36). All of our irHLH cases presented with hyperferritinemia greater than 3000 µg/L, even those with an HScore as low as 162, and 137 138 showed conventional biological changes such as hepatitis, renal dysfunction, cytopenia, 139 hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis in the bone marrow and

spleen (although only three patients were biopsied). In addition, elevated levels of soluble
CD25 (IL-2R) and key clinical features such as persistent fever and multi-organ dysfunction
were observed in all cases.

143 Among the irHLH patients, 1 of the 9 patients was classified as irCRS G3 and 8 were 144 classified as irCRS G4. None of the non-irHLH patients were classified as G4. Melanoma 145 and lung cancer were the two most common types of cancer, with 17 out of 35 patients (49%) 146 and 11 out of 35 patients (31%) respectively. Treatments modalities included anti-PDL-1 for 147 3 patients (9%), anti-PD-1 for 11 (32%), anti-PD-1 and anti-CTLA4 combination for 21 patients (60%) and chemo-immunotherapy for 9 patients (25.7%). The median follow-up 148 149 after the first ICI administration was 29.5 months (95% CI: 13.68-44.44). Of the 28 patients 150 with irCRS, 3 (11%) received corticosteroids (CS) alone, 13 (46%) received CS combined 151 with tocilizumab (TCZ), and 12 (43%) did not receive any immunosuppressive treatment. 152 Patients treated with anti-PD-1 and anti-CTLA4 combination therapy had a higher frequency 153 of high-G (G3, G4) irCRS (75%, n=12/16) compared to those treated with anti-PD-1 154 monotherapy (25%, n=4/16). The median time to the onset of low- and high-G irCRS was 1.3 155 months (95% CI: 0.23-26.1) and 2.5 months (95% CI: 1.35-5.46), respectively.

156

157

#### Comprehensive cytokine and biological profiles across different clinical grades of irCRS

To characterize the inflammatory profile of irCRS, we analyzed a large panel of classical and inflammatory biomarkers in patients with different clinical grades (G1 to G4). Of the 28 patients analyzed for irCRS, three were excluded from cytokine analysis due to ongoing immunosuppression at the time of samples collection. All other patients were screened for cytokines after referral to the Service of Immunology and Allergy prior to initiation of immunosuppression. Standard laboratory tests showed a significant association between irCRS severity and elevated levels of aspartate aminotransferase (AST), alanine

aminotransferase (ALT), alkaline phosphatase (AP), gamma-GT (GGT), and ferritin, as well
as decreased levels of fibrinogen (Fig. 1a-1c). Notably, coagulation abnormalities escalated
with irCRS severity, characterized by elevated d-dimer levels and reductions in platelets,
fibrinogen, prothrombin ratio, and activated partial thromboplastin time. The coagulopathy
was particularly pronounced in grade 4 (G4) patients (Fig. 1b-1c).

170 With regard to the analysis of the serum levels of a large panel (n=45) of cytokines/chemokines and growth factors, 14 were found to be increased as compared to 171 172 baseline, i.e. prior to the initiation of ICI therapy and correlated with the irCRS grade severity. These included the chemokines CXCL9, CXCL10, CXCL13, CCL2, CCL3, CCL4, 173 174 CCL5 and CCL11 (Fig. 1d-1f,), the growth factors SCF and HGF, (Fig. 1g), the 175 inflammatory cytokines IL-6, IL-18 and IFN- $\gamma$ , and the anti-inflammatory cytokines IL-1RA 176 and IL-10. (Fig. 1h). Analysis of anti-inflammatory cytokines revealed an increase in IL-1RA 177 in all irCRS grades with irCRS severity, and a significant increase in IL-10 levels in G4 (Fig. 178 1e).

179 By analyzing the correlation matrix of biomarkers across all irCRS patients, a complex network of positive and negative correlations was revealed. CRP showed a positive 180 181 correlation with ferritin, IL-18, IL-6 and ALP, but a negative correlation with Hb. Inversely, 182 Hb showed a negative correlation with IL-6 (Supplementary Figure 2a). Ferritin, a key 183 marker of inflammation, correlated with a wide array of biomarkers, including PDGF-B, CCL2, HGF, SCF, CXCL13, CXCL9, IL-18, ALT, AST, CCL3, IL-1RA, CXCL10, CRP, 184 185 CXCL1, IL-10, IFN- $\gamma$ , and ALP (**Supplementary Figure 2**). Certain biomarker correlations 186 were specific to patients with high-G and not observed in low-G such as IFNy/IL-1RA, IL-187 10/HGF, IL-10/IL-1RA, IL-10/ferritin, d-dimer/ferritin, CRP/ferritin, HGF/ferritin and 188 ALT/Hb (Supplementary Figure 2d-h,m,n,o) In contrast, other biomarker pairs, including CXCL10/CXCL9, PDGF-BB/EGF and CXCL9/ferritin exhibited correlations in both low-G 189

and high-G (Supplementary Figure 2b, c, l). However, fibrinogen/ferritin and IL-6/Hb
showed predominantly negative correlations in high-G (Supplementary Figure 2i, p).
Therefore, these results indicated that a immunological markers are increased in patients with
irCRS, they correlate with the severity of the clinical grading, and are positively or negatively
correlated with conventional biological markers.

195

#### 196 Variations in immune cell subsets are associated with clinical severity of irCRS.

197 Due to the limited sample size, we pooled mass cytometry data of patients into low-G (G1, 198 G2) and high-G (G3, G4) for analysis. As we observed multiple differences in several 199 immune subsets, we will only describe the most profound variations common to both low and 200 high G irCRS (Supplementary Figure 3, p values in Supplementary File 1). The analysis 201 of T-cell dynamics reveals a significant increase in several activated memory T cell subsets 202 of CD4+ and CD8+ T cells, such as central memory (CM), transitional memory (TM), and 203 effector memory (EM). These subsets were characterized by HLA-DR+ and CD38+ 204 expression (Supplementary Figure 3a-3b). Additionally, we observed an increased 205 frequency of CD38+ monocytes in classical (CL), intermediate (ITM), and non-classical 206 memory (NCL), and a decrease in CD141+ DC, conventional mDC, and pDC 207 (Supplementary Figure 3c and 3e). Mature neutrophils decreased while immature 208 neutrophils and all CD38+ and CD62L+ neutrophil subsets increased (Supplementary 209 Figure 3f). Other subsets showed no significant changes (Supplementary Figure 3d-3g). 210 The only major difference between high and low-G was the decreased frequency of switched 211 memory (SM) IgA2+ B cells and CXCR3+ NCL monocytes in low-G (Supplementary 212 Figure 3).

213

#### 214 Identification of clusters with different survival linked to distinct cytokine profiles by

#### 215 using classical biomarkers.

216 It was then determined whether distinct biomarkers profiles defined different survival groups 217 based on their biomarkers profile. We thus performed K-means unsupervised clustering and 218 several biomarkers were considered, including those used in the HScore, alone (Fig. 2c), 219 combined with CRP (Fig. 2d, supplementary Table 4) or creatinine (Fig. 2e) or both (Fig. 220 2f, Supplementary Table 4). To determine the optimal number of clusters, K-means 221 clustering was evaluated for 1 to 4 clusters using the silhouette method. An example of the 222 clustering performance on the PCA dimension-reduced plot for clusters C1 to C3 (Fig. 3a) 223 and the corresponding silhouette curve (Fig. 3b) are shown. The HScore alone did not 224 allowed identification of clusters associated with different survival from the onset of irCRS. 225 However, the addition of biomarkers such as CRP and creatinine improved clustering 226 performance. Using this approach, the most insightful results were obtained when multiple 227 biological biomarkers were combined, including CRP, ferritin, creatinine, AST, ALT, total 228 bilirubin, PAL, GGT, leukocytes, neutrophils, and Hb (Fig. 3). This approach led to the 229 identification of three distinct patient clusters in a two-steps approach (Fig. 3a-3b and 230 **Supplementary Table 5**). First, a cluster of three patients (Cluster 3) with significantly lower 231 survival from irCRS onset and a combined cluster (1+2) were identified (Fig. 3a, 3c). On the 232 remaining combined cluster (1+2), optimal clustering identified two distinct clusters, Cluster 233 1 and Cluster 2. Survival outcomes from the onset of irCRS differed significantly among the 234 three clusters. Cluster 1 showed the most favorable prognosis, with a 100% 2-year survival 235 rate, Cluster 2 presented an intermediate survival outcome, with 47% of patients surviving at 236 2 years and Cluster 3 had a 0% survival rate at 6 months (Fig. 3c). These survival trends 237 were further supported by distinct profiles of overall survival (OS) and survival from the 238 initiation of ICI treatment (Fig. 3c). Interestingly, the three clusters showed different patterns

239 of clinical severity. Cluster 1 had a mixed composition of high-G cases, including both grade 240 3 (G3) and grade 4 (G4) irCRS cases whereas cluster 2 was predominantly low-G with 75% 241 of cases. Notably, cluster 3 was characterized exclusively by the presence of three patients 242 with irHLH thus confirming being the cluster associated with the most severe clinical 243 presentation (Fig. 3d). Further delineation of clusters differences through biological profiling 244 revealed that cluster 3 was also associated with the highest degree of biological perturbations 245 and impact on multiple organs. Significant abnormalities were observed in markers of liver 246 (AST, ALP) and kidney (creatinine) functions, of inflammatory markers (CRP, ferritin, 247 lymphopenia), of coagulation (prothrombin ratio, activated partial thromboplastin time, d-248 dimer), and hematology (anemia) (Fig. 3e-3h).

249 Additional characterization through immune profiling revealed that Cluster 3 was 250 characterized by a highly inflammatory profile with elevated levels of various cytokines (IL1-251 RA, IL-6, IL-10, IL-18, IFN-γ), chemokines (CCL2, CXCL8, CXCL9, CXCL10, CXCL12, 252 CXCL13), and growth factors (HGF, SCF) (Fig 3i-3k). This inflammatory profile indicates a 253 robust reactive inflammatory response, likely contributing to the clinical severity observed in 254 Cluster 3. To assess the individual weight of different biomarkers on survival after the onset 255 of irCRS, a 1D K-means clustering technique was applied to all measured cytokines and 256 biological biomarkers, followed by univariate Cox proportional hazards modeling. As shown 257 in Supplementary figure 4a-4b, this methodological approach facilitated the identification 258 of high and low clusters for each biomarker, including creatinine, hemoglobin, and 259 prothrombin ratio. Analysis revealed that clusters characterized by high creatinine, low 260 hemoglobin, or low prothrombin ratio were significantly correlated with reduced survival 261 after irCRS onset. The results showed a hazard ratio (HR) of 5.605 (p=0.0068) for the high 262 creatinine cluster, an HR of 6.643 (p=0.015) for the low hemoglobin cluster, and an HR of 263 5.811 (p=0.0324) for the low prothrombin ratio cluster (Supplementary Figure 4a). These

264 findings were further supported by distinct Kaplan-Meier survival curves, showing the 265 negative impact of these biomarker levels on patient outcomes post-irCRS onset (Supplementary Figure 4c-4e). Interestingly, when dual biomarkers such as hemoglobin and 266 creatinine were combined for survival prediction, the accuracy was significantly improved. 267 However, the predictive value reached its peak - 100% accuracy - when hemoglobin, 268 269 creatinine and prothrombin ratio were integrated into a unified clustering model 270 (Supplementary Figure 4f-4g). This improvement in prognostic prediction by a multi-271 biomarker approach highlights the substantial benefits of including a combination of 272 biological markers to assess survival outcomes in irCRS patients.

273

# Biomarker performance in differentiating irCRS Grade 3 from irHLH and predicting clinical severity and tocilizumab therapy escalation.

276 As mentioned above, the primary objective was to identify biomarkers to improve diagnostic 277 accuracy, the evaluation of clinical severity and to predict treatment intensification in patients 278 with irCRS and irHLH. 45 serum biomarkers were evaluated including cytokines and 279 biological markers in addition to those present in the traditional HScore(31). Our results 280 confirmed the significant limitations of the HScore in the assessment of severe irCRS in 281 patients with high-G irCRS. In fact, certain patients, despite low HScore, required escalating 282 treatment with tocilizumab (TCZ), as observed in patients 2, 7, 9, and 11 (Supplementary 283 Figure 5a). In irHLH patients, an HScore above 154 achieved 100% diagnostic sensitivity, 284 identifying 2 patients with low HScore HLH probability (41% and 61%) (31) (Fig. 4a). In 285 addition, a strong correlation was found between higher ferritin levels and increased clinical severity in patients with irHLH (**Fig. 4b**), with median ferritin levels > 148000 in the irHLH 286 287 group well above the established highest HScore cutoff of 6000 (Fig. 4c). These results 288 highlight the limitations of the traditional ferritin threshold of 6000 of the HScore (31) in this

context, which adds only 50 points and thus fails to capture the full extent of the inflammatory state associated with irHLH, where ferritin could rise to much higher levels.

291

292 Based on these limitations, we attempted to identify the most reliable predictive biomarkers 293 differentiating between irHLH and irCRS G3. As detailed in the demographics, all the irCRS 294 G4 were irHLH. Of the irCRS G3, one patient was irHLH but was excluded from the 295 biomarker analysis because the biomarker panel was performed after initiation of 296 immunosuppressive treatment. We analyzed 45 biomarkers including, 27 cytokines, 18 297 biological markers including those of the HScore. We determined the cutoff values, area 298 under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive and 299 negative predictive values, and accuracy. This analysis identified a panel of 24 biomarkers 300 with P-values below 0.05, ranging from <0.0455 to <0.0027 (HGF, ferritin, SCF, IL-10, IL-301 18, CCL4, aPTT, IL-1RA, CCL2, D-dimer, PDGF-BB, CXCL8, prothrombin time ratio, 302 CXCL9, CCL11, LIF, ASAT, CXCL10, fibrinogen, CCL3, IL-6, CXCL13, IFN-γ and 303 platelets) that significantly discriminated between irHLH and irCRS G3 (Fig 4d). Among 304 them, HGF, ferritin, IL-1RA, prothrombin time ratio, CXCL9 and fibrinogen showed the 305 highest sensitivity (100%) with specificity ranging from 66% to 100%. Remarkably, HGF 306 and ferritin showed excellent 100% accuracy whereas the sensitivitythat of the HScore was 307 only 71.43% (Fig 4d). Importantly, only CXCL9 and total bilirubin were significantly 308 predictive of treatment intensification with TCZ, with sensitivities of 75 (CXCL9) to 100% 309 (bilirubin) and specificities of 77.78% (bilirubin) to 100% (CXCL9) whereas the specificity 310 of HScore was 66.67% (Fig 4e). Regarding hemodynamic instability requiring fluid 311 resuscitation, HGF, SCF and aPTT were the best predictors with 100% accuracy, whereas the 312 accuracy of the HScore was only 76.92% (Supplementary Figure 5b). For respiratory 313 distress, CCL2, ferritin, D-dimer and aPTT were the only markers with 100% positive

predictive value and sensitivity, with specificity ranging between 71.43-85.71%, wheras the
HScore had 83.3% accuracy and 85.71% positive predictive value (Supplementary Figure
5c).

317

#### 318 High-grade irCRS and sepsis patients exhibit distinct biomarker profiles.

319 Although patients with high-G irCRS and sepsis may present with similar clinical 320 manifestations, it is crucial to differentiate between these two conditions. For these purposes, 321 we compared the biomarker levels of patients with irCRS G3 or irHLH to those of patients 322 with sepsis and identified a cytokine and immune cell signature that distinguished them. The patients with irHLH had significantly higher levels of IL-10 and IL-1RA (Supplementary 323 324 Figure 6a and 6d). sCD25 was not significantly different between groups (p=0.08), but IL-6 325 was highest in sepsis compared to irCRS G3 (Supplementary Figure 6a, 6d). IFN- $\gamma$ 326 pathway was observed in irHLH, as indicated by significant increases in IFN- $\gamma$ , CXCL-9, 327 CXCL-10 and IL-18, as well as CCL3 and CCL4, compared to sepsis and irCRS G3 328 (Supplementary Figure 6a and 6b). IL-7 was significantly increased in sepsis 329 (Supplementary Figure 6a). HGF was higher in irHLH compared to sepsis and irCRS G3, 330 whereas EGF and GM-CSF were higher in sepsis compared to irCRS G3 (Supplementary 331 Figure 6c). SCF and LIF were higher in irHLH compared to irCRS G3 (Supplementary 332 Figure 6d). Leukocytes and neutrophils were higher in sepsis compared to irHLH and irCRS 333 G3 (Supplementary Figure 6e). Ferritin, D-dimer, and transaminases were more elevated in irHLH than in sepsis and irCRS G3 (Supplementary Figure 6f). Furthermore, irHLH 334 335 showed more severe coagulopathies, including prothrombin ratio and fibrinogen levels (Supplementary Figure 6g). Mass cytometry analysis between high-grade irCRS (irHLH 336 337 and G3) and sepsis (Supplementary Figure 7, p values in Supplementary File 2), 338 identified CD38+ HLA-DR+ double-positive T cells as increased in the CM, EM, and TM

339 subsets. Compared to sepsis, there was a significant increasing trend of CD4 memory CD38+, 340 CD4 TM HLA-DR+/CD38+, CD8 memory CCR4+, and a decrease in CD8 memory 341 CXCR5+ in high-grade irCRS. (Supplementary Figure 7a and 7b). Compared to sepsis, 342 there was a significant increase in the frequency of CD38+ monocytes in the ITM subset. 343 Additionally, there was a significant increasing trend in CL monocytes CD11c+ and CL 344 monocytes CD38+ and in the frequency of CD16 NK cell (Supplementary Figure 7d-7e). 345 Compared to sepsis, high-G irCRS exhibited decreased total neutrophils but increased 346 CD62L neutrophils in both immature and mature subsets (Supplementary Figure 7f). No 347 significant differences were observed in the other subsets (Supplementary Figure 7d, 7e 348 and 7g).

349

350

#### 351 Discriminating irCRS Grade 3, irHLH, and sepsis through circulating biomarkers

352 The potential of all biomarkers to discriminate between irCRS grade 3, irHLH and sepsis at 353 the time of diagnosis was evaluated. Multiple supervised approaches were used to evaluate 354 this In the first approach, we analyzed 46 biomarkers including 27 cytokines, and 18 355 biological markers. We determined cutoff values, area under the receiver operating 356 characteristic curve (AUC), sensitivity, specificity, positive and negative predictive values, 357 and Youden's J index for each biomarker. This analysis identified a panel of 11 biomarkers 358 (leucocyte count, IL-7, fibrinogen, EGF, CXCL10, neutrophils, GM-CSF, ALAT, ALP, GGT 359 and IL-6) that significantly discriminated between sepsis and irCRS high-G with P-values 360 ranging from <0.0046 to <0.0415 (Fig. 5a). Among the biomarkers tested, leukocyte count, 361 IL-7, fibrinogen, EGF, CXCL10, and neutrophils demonstrated the highest sensitivity (100%) 362 with an excellent specificity of 92.31% (Fig. 5a). In addition, a panel of 10 biomarkers 363 (leucocyte count, neutrophils, IL-6, EGF, ALP, IL-7, GM-CSF, fibrinogen, IL-15 and

364 CXCL10) was identified and significantly discriminated between sepsis and irCRS G3 with 365 P-values ranging from <0.0082 to <0.0472 (Fig. 5b). Among the measured parameters, leukocyte count, neutrophils, IL-6, and EGF exhibited an accuracy of 100% (Fig. 5b). In 366 367 addition, the ferritin cut-off of 23221 ng/ml was discriminating between irHLH and the rest 368 of patients (sepsis and irCRS G3) with sensitivity and specificity of 100 % (ROC p value of 369 0.0009) (Fig. 5c and Supplementary Table 6). Two additional supervised approaches were 370 used. First using sPLS-DA (Sparse Partial Least Squares Discriminant Analysis), we found 371 that the biomarker profiles could effectively separate the three conditions, with only one 372 irCRS case falling between the irCRS and Sepsis clusters (Supplementary Figure 8a). 373 sPLS-DA first component identified 5 biomarkers with absolute importance higher than 0.3: 374 IL-10, HGF, IL-18, IL-1RA, and SCF (Supplementary Figure 8b). Component 2 identified 375 three variables exceeding 0.3: leukocytes count, IL-7, and EGF (Supplementary Figure 8c). 376 Component 1 explained most of the X axis variation notably the separation of irHLH patients 377 identifying biomarkers previously found using the ROC curve approach (*i.e* IL-10, HGF) and 378 component 2 the Y axis separating the sepsis from the irHLH identifying also biomarkers 379 identified in Figure 5 (*i.e* leucocytes count, IL-7, EGF). The potential for developing a 380 decision tree construction was explored using the random forest algorithm to identify the 381 most predictive biomarkers for classification. Ferritin emerged as the most abundant initial 382 node in the decision trees, with ferritin, HGF, and leukocyte count ranking as the top three 383 biomarkers based on their average Gini coefficient across 100 trees (Supplementary Figure 384 8d and 8e). 385 Our aim was to develop a decision tree capable of distinguishing the three CRS-like

385 Our aim was to develop a decision tree capable of distinguishing the three CRS-like 386 presentations within our cohort. Using ferritin with a threshold of >23111 ug/L, 100% 387 accuracy was achieved in discriminating irHLH patients from those with irCRS G3 or sepsis. 388 Eight additional markers (CCL4, HGF, IL-1RA, IL-10, IL-18, fibrinogen, CXCL9 and

389 aPTT) have higher than 90% accuracy to identify irHLH patients from irCRS-G or sepsis 390 (Supplementary Table 6). The differentiation between irCRS G3 and sepsis was further refined using three biomarkers-EGF, IL-6, and leukocytes-with specific thresholds. EGF 391 392 (>51.3 pg/mL), IL-6 (>129.6 pg/mL), and leukocytes (>8.5 G/L), that allowed perfect 393 separation between these conditions. The integration of these biomarkers facilitated the 394 prediction of irHLH, irCRS G3, and sepsis with 100% accuracy within our cohort (Figure 395 5d). Neutrophils count also have a 100% accuracy (Figure 5b) but was not included in the 396 tree due to the lack of measurement in 1 sepsis patients. This multifaceted biomarker analysis underscores the effectiveness of integrating multiple immune profiling techniques to 397 398 precisely distinguish between irCRS, irHLH and sepsis, which is critical for guiding 399 appropriate therapeutic interventions in these clinically challenging scenarios.

#### 400 Tocilizumab is effective treatment of corticosteroid refractory high-grade irCRS.

401 Twelve patients with severe high-G irCRS received adjunctive therapy with TCZ, an anti-IL-402 6R antagonist, due to a suboptimal initial response to corticosteroids. TCZ use in 403 irCRS/irHLH patients adheres to our standard care in combination where it is employed as a 404 second-line escalation therapy in corticosteroid-sparing strategies, or as an initial 405 combination therapy with corticosteroids in severe CRS cases. This in accordance to our 406 previous work (15) which contributed to our involvement in developing the irHLH ESMO 407 guidelines(1). These patients' data were retrospectively collected, and out of these 12 408 patients, 3 were not included in the rest of the manuscript as their cytokines were only 409 collected after TCZ initiation. Encouragingly, a 100% response rate to treatment with TCZ 410 was observed, resulting in rapid and substantial clinical improvements. Importantly, all cases 411 of irHLH were resolved and no irCRS-related mortality was observed at either 7 or 30 day 412 (Supplementary Table 2). Longitudinal cytokine follow-up data were available for only 6 413 out of 12 patients. In this subgroup, standard markers of inflammation such as cytolysis,

- 414 ferritin levels, C-reactive protein (CRP) and leukopenia showed significant reductions and
- 415 normalization (Fig. 6a). Similarly, TCZ treatment induced significant reductions in all
- 416 immunological markers including IFN-γ, soluble CD25 (sCD25), IL-6, IL-18, CXCL9,
- 417 CXCL10, CCL2, CCL4, CCL5, HGF, SCF, IL-10 and IL-1RA (Fig. 6b). Importantly, TCZ
- therapy did not result in any significant adverse events.
- 419
- 420
- 421

#### 422 Figures legend

423 Figure 1. Comprehensive cytokine and biological profiles for different clinical grades of 424 irCRS. (a-c), Evaluation of serum biomarkers in patients (n=28) at the time of irCRS 425 compared to the pre-ICI serum levels in 194 cancer patients used as reference group. (d-g) 426 Serum levels of chemokines, growth factors and cytokines in 25 patients with different 427 clinical grades at irCRS diagnosis compared to the pre-ICI serum levels in 194 cancer 428 patients used as reference group. Student T test tests were used to analyze the data for 429 statistical significance between groups, irCRS G1 were not compared to other clusters due to 430 the low number of patients (n=2). Plots represent values with individual data points, bar 431 represent the mean and error bars represent standard deviation. The results showed a 432 significant difference between the groups with a P-value of less than 0.001 (\*\*\*P<0.001) and less than 0.0001 (\*\*\*\*P<0.0001). 433

434

435 Figure 2. Exploration of 4 distinct clusterings across HScore and other biological 436 parameters reveals variable strengths regarding survival from irAE. Biological 437 parameters were collected from irCRS patients at the time of diagnosis (n=28). (a) clustering 438 plot for the three identified clusters based on HScore parameters. (b) silhouette plot showing 439 the optimal number of clusters based on HScore parameters. (c) Kaplan-Meier (KM) plot showing the survival rate from irCRS onset for the three Clusters (C1, C2, C3) obtained using 440 441 HScore parameters. (d) KM plot showing the survival rate from irCRS onset for the four 442 Clusters (D1, D2, D3, D4) obtained using a combination of HScore parameters and CRP. (e) 443 KM plot showing the survival rate from irCRS onset for the three Clusters (E1, E2, E3) obtained for the four Cluster (F1, F2, F3, F4) using a combination of HScore parameters and 444 445 creatinine. (f) KM plot showing the survival rate from irCRS onset using a combination of HScore parameters, creatinine, and CRP. Log-rank tests were used to analyze the data for 446

statistical significance between groups and to calculate confidence intervals (CI) and hazardratios (HR).

449 Figure 3. Integration of additional circulating biomarkers enhances clustering linked to 450 distinct overall survival and cytokine profiles. The biomarkers used for this other clustering are CRP, ferritin, creatinine, AST, ALT, total bilirubin, ALP, GGT, leukocytes, 451 452 PNN and Hb collected from irCRS patients at the time of diagnosis (n=28). (a) Clustering 453 plot initially identified two distinct clusters: combined Cluster 1+2, and Cluster 3. (b) After 454 isolating the three patients belonging to cluster 3, K means clustering was applied to the remaining cohort, resulting in the separation of the combined Cluster (1+2) into two new 455 456 distinct clusters, labeled as Cluster 1 and Cluster 2 (c) Kaplan-Meier plot showing the 457 survival rate for the three identified clusters, Cluster 1 (n=7), Cluster 2 (n=18) and Cluster 3 458 (n=3), the survival from irCRS onset, the overall survival (OS) or the survival from ICI 459 initiation. (d) distribution of the irCRS according to the clinical grade in each cluster. (e-h) 460 comparison of levels of circulating blood cells and serum biomarkers, including liver and 461 kidney functions, coagulation and inflammation parameters in each cluster. (i-k) comparison of serum cytokine, chemokine, and growth factor levels among the three clusters. Log-rank or 462 463 Mantel-Haenszel (if a cluster had 0 deaths during the interval) was used to calculate CI, HR, 464 and p values for the KM curves. Student T tests were used to analyze the data for statistical 465 significance of biomarkers levels between groups. Panels E to K plots represent values with 466 individual data points, bar represent the mean and error bars represent standard deviation. CI, 467 Confidence Interval; HR, Hazard Ratio, CRP: C-reactive protein; Hb: hemoglobin; PNN: 468 polynuclear neutrophils; AST: aspartate aminotransferase; ALT: alanine transaminase; ALP: 469 alkaline phosphatase; GGT: gamma glutamyl transferase.

470

471 Figure 4. Superior performance of HGF and ferritin in discriminating between irCRS 472 G3 and irHLH, with CXCL9 and total bilirubin predicting tocilizumab therapy 473 escalation. (a) Comparison between the real diagnosis of high-G irCRS and estimation of 474 diagnosis based to the conventional HScore. (b) Linear regression and correlation coefficient 475 between ferritin and HScore in patients with irCRS G3 (n=7) or irHLH (n=6). (c) Median 476 ferritin (pg/mL) in patients with irCRS G3 (n = 7) or irHLH (n = 6). (d) performance (area 477 under the receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and 478 negative predictive values) of each marker to discriminate irHLH (n=6) from irCRS G3 479 (n=7). (e) Performance (area under the receiver operating curve (AUC), cut-off value, 480 sensitivity, specificity, positive and negative predictive values) of each marker in the 481 prediction of treatment intensification with TCZ in patients with high-G irCRS (n=13). 482 Confidence intervals for specificity and sensitivity have been calculated using Wilson-Brown 483 method. Panel c plot represent values with individual data points, bar represent the mean and 484 error bars represent standard deviation.

485

Figure 5. Distinct biomarker profiles in irCRS G3, irHLH and sepsis allow differential 486 487 diagnosis. (a) Performance (area under the receiver operating curve (AUC), cut-off value, 488 sensitivity, specificity, positive and negative predictive values) of each marker to 489 discriminate sepsis (n=4) from high-G irCRS (n=13). (b) Performance of each marker to 490 discriminate sepsis (n=4) from irCRS G3 (n=7). (c) ferritin levels in patients with irHLH 491 (n=6) vs irCRS G3 and sepsis (n=4) with area under the receiver operating curve (AUC), cut-492 off value, sensitivity, specificity. (d) Decision tree analysis showing the performance of each 493 biomarker in discriminating between irCRS G3, irHLH and sepsis. Confidence intervals for 494 specificity and sensitivity have been calculated using Wilson-Brown method. Of note, 495 neutrophil count, alkaline phosphatase, and gamma-GT were only performed in 3 sepsis

patients because one patient had missing measurements at the time of inclusion. Panel c plot
represent values with individual data points, bar represent the mean and error bars represent
standard deviation.

499

Figure 6. Longitudinal biomarker changes and biological resolution in CS-Refractory High-G irCRS patients treated with tocilizumab. (a) Evolution of serum biomarker levels including AST (UI/L), CRP (mg/L), ferritin (μg/L), leukocytes (G/L), and (b) serum cytokine, chemokine, and growth factor levels, in patients with repeated cytokines measurements receiving tocilizumab treatment for CS-refractory high-grade irCRS (n=6). The gray boxes in panel a indicate the global period of tocilizumab treatment, while the arrows in panel b indicate individual days of tocilizumab administration.

507

508 Supplementary Figure 1: Study flowchart

509

510 Supplementary Figure 2: Correlation between cytokine and biological biomarkers by 511 clinical grade of irCRS. (a) Spearman Correlation Matrix. Correlation map plotted using 512 significance levels for the Spearman test performed with relevant serum biomarker data from 513 all irCRS patients studied across all grades. Positive correlations are shown in shaded blue 514 and negative correlations are shown in shaded red. Correlations with a p-value  $\geq 0.05$  are not 515 considered significant and are left blank. Color intensities are proportional to the correlation 516 coefficients. On the right side of the correlogram, the color legend shows the correlation 517 coefficients and corresponding colors. (**b-q**) Correlation and linear regression between the 518 level of various serum biomarkers including cytokines and biological parameters according to 519 the clinical severity, low-grade (G1, G2) (n=12) in orange versus high-grade (G3, G4) (n=16)

in blue. Each point represents a unique patient time point at irCRS diagnosis. Spearman'srank correlation coefficient and significance are shown.

522

523 Supplementary Figure 3: Comprehensive profiling of circulating immune cell phenotypes differentiates high from low irCRS grades. (a-g) Heatmap showing fold 524 525 change relative to pre-ICI baseline of cancer patients (n=103) of the different immune cell 526 subsets in patients at the time diagnosis of low-G irCRS (n=10) vs high-G irCRS (n=10). (a) 527 CD4 T cell subsets, (b) CD8 T cell subsets, (c-e) monocyte subsets, (f) NK cells, NKT cells 528 and TCR $\gamma\delta$  T cells, (g) dendritic cells DCs, (h) neutrophils, (i) B cells. Values represent % of 529 parent population as indicated in the gating strategy (Supplementary\_OLD Figure 2). 530 Statistical significance was analyzed using Student T test between groups. \*\*\*P<0.001, 531 \*\*\*\*P<0. EM: effector memory, CM: central memory, DC: dendritic cells, TEMRA: 532 terminally differentiated effector memory cells re-expressing CD45RA, classical monocytes 533 CL, intermediate monocytes ITM, and non-classical monocytes NCL

534

Supplementary Figure 4: 1d K-Means clustering of biological parameters reveals high 535 536 and low clusters with differential impact on survival from irAEs. (a) Univariate Cox 537 regression models for OS with the different high and low clusters identified by K-means 538 clustering for various biomarkers (n=28). (b) Biomarkers levels in the different identified low 539 and high clusters. (c) Kaplan-Meier curves illustrating the survival from irCRS onset in low 540 (n=4) and high (n=23) creatinine clusters. (d) Survival in low (n=14) and high (n=14)541 hemoglobin clusters. (e) Survival in low (n=2) and high (n=26) prothrombin ratio clusters. (f) 542 Kaplan-Meier plot showing the survival rate for the three Clusters, Cluster eF1 (n=4), Cluster 543 eF2 (n=14) and Cluster eF3 (n=10), identified with K-means using hemoglobin (Hb) and 544 creatinine, (g) Kaplan-Meier plot showing the survival rate for the four clusters, Cluster eG1

(n=4), Cluster eG2 (n=14), Cluster eG3 (n=6) and Cluster eG4 (n=4) identified with K-means
using creatinine, Hb and Prothrombin ratio. Log-rank (Mantel-Cox) test was used to identify
significant differences between groups in panels F and g, logrank for comparing two clusters
in c to e.

549

550 Supplementary Figure 5: Biomarker efficacy in the prediction of hemodynamic 551 instability and respiratory distress in patients with high-G irCRS. (a) clinical and 552 treatment characteristics of all patients with high-G irCRS (n=13). (b) Performance (area 553 under the receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and 554 negative predictive values) of each marker in the prediction of hemodynamic instability 555 requiring vasopressor in patients with high-G irCRS (n=7). (c) performance (area under the 556 receiver operating curve (AUC), cut-off value, sensitivity, specificity, positive and negative 557 predictive values) of each marker in the prediction of respiratory distress in patients with high-G irCRS (n=13). Confidence intervals for specificity and sensitivity have been 558 559 calculated using Wilson-Brown method. TCZ: tocilizumab

560

561 Supplementary Figure 6: Cytokine and Biological profiles for irCRS G3, irHLH and 562 Sepsis. (a-d) comparison of serum cytokine, chemokine, and growth factor levels. (e-g) 563 circulating blood cells and serum biomarker levels (including liver and kidney functions, 564 coagulation and inflammation parameters) in the three groups of patients: irCRS G3 (n=7), 565 irHLH (n=6) and sepsis (n=4). Panels A to G plots represent values with individual data 566 points, bar represent the mean and error bars represent standard deviation. Statistical 567 significance was analyzed using Mann-Whitney test between groups. \*\*\*P<0.001, 568 \*\*\*\*P<0.0001.

569

570 Supplementary Figure 7: Comparative distribution of circulating immune cell 571 populations in patients with irCRS G3, irHLH or sepsis. (a-g) Heatmap showing fold 572 change relative to pre-ICI baseline of cancer patients (n=103) of the different immune cell 573 subsets in patients with irCRS G3 (n=4), irHLH (n=6) or sepsis (n=5). (a) CD4 T cell subsets, 574 (b) CD8 T cell subsets, (c-e) monocyte subsets, (f) NK cells, NKT cells and TCR $\gamma\delta$  T cells, 575 (g) dendritic cells DCs, (h) neutrophils, (i) B cells. Values represent % of parent population 576 as indicated in the gating strategy (Supplementary\_OLD Figure 2). Statistical significance was analyzed Student T tests between groups. \*\*\*P<0.001, \*\*\*\*P<0.0001. EM: effector 577 memory, CM: central memory, DC: dendritic cells, TEMRA: terminally differentiated 578 579 effector memory cells re-expressing CD45RA, classical monocytes CL, intermediate 580 monocytes ITM, and non-classical monocytes NCL

581

582 Supplementary Figure 8: Clustering of circulating biomarkers provides distinction 583 between irCRS, irHLH and sepsis. (a) Supervised learning sPLS-DA approach used to 584 separate the three subgroups: irCRS G3, irHLH and sepsis. (b) The variables of component 1 585 allow for the separation of irHLH from the other 2 groups. (c) The variables of component 2 586 allow the separation of irCRS grade 3 from sepsis. (d) random forest averaged Gini 587 coefficient across 100 forest for all biomarkers. (e) Percentage as the main node of trees for 588 all biomarkers. sPLS-DA: sparse partial least squares discriminant analysis.

589

590 Supplementary Figure 9: Gating strategy for mass cytometry. Complete gating strategy591 identify the main population with the list of antibodies and coupled antibodies.

592

Supplementary Table 1: Patients, treatments, and clinical characteristics. The principal
clinical, demographic, and therapeutic data for the entire cohort (n=35) are presented in detail
in this table.
Supplementary Table 2: clinical characteristics of irCRS patients receiving Tocilizumab
treatment (n=12).
Supplementary Table 3: Global biomarker table. Summary table with for irCRS G1-G4,
Bacterial sepsis, Viral sepsis, Immunosuppressed patients: N, Mean, Min, Max, Percentiles
(25th,50th,75th) and SD. Lower limit of detection is included in the table for all biomarkers.
Supplementary Table 4: HR and P values associated with Figure 2 panels D and F. logrank
test for comparing clusters in Figure 2 panels D and F
Supplementary Table 5: Clinical characteristics of irCRS patients within clusters identified
in Figure 3
Supplementary Table 6: ROC curve analysis of predictors of irHLH versus irCRS-
G3/Sepsis patients. ROC, AUC and p values, cutoff, Sensitivity, Specificity, Accuracy,
Positiva predictiva value and Nagativa predictiva value
rositive predictive value and riegative predictive value
rositive predictive value and riegative predictive value
Supplementary File 1: P values for comparison of mass cytometry data comparing either
<b>Supplementary File 1:</b> P values for comparison of mass cytometry data comparing either Low grade or high-grade patients with baseline. Statistical significance tested with Mann-

618	В
-----	---

619	Supplementary File 2: P values for comparison of mass cytometry data comparing either
620	high grade or sepsis patients with baseline. Statistical significance tested with Mann-Whitney
621	test.
622	

623

#### 624 Material and Methods

#### 625 Sample collection and ethic approval

All patients either signed informed consent offered to all patients to allow research use of their data in a coded fashion (called "*consentement general*") or did not express opposition and were included thanks to article 34 of the Swiss federal law relative to human research. Research protocol was approved by the cantonal ethical committee "*Commission cantonal d'éthique de la recherche sur l'être humain (CER-VD)*". All samples were harvested during the normal clinical practice, and no specific intervention on patients were performed regarding this study.

633

#### 634 Immune profiling of circulating blood immune cells population by mass cytometry

Patient blood was stained as previously described (*37*). Briefly, cells were incubated for 30
min at room temperature (RT) with a 50µL antibody cocktail of metal-conjugated antibodies.
Cells were then washed and fixed with 2.4% PFA for 10 min at RT, lysed for 15□ min at RT
using Bulklysis solution (Cytognos), and incubated 30□ min at RT with metal-conjugated
antibodies. Complete list of metal-conjugated antibodies and gating strategy can be found as
Supplementary Figure 9. Cells were washed and total cells were identified by DNA
intercalation (1µM Cell-ID Intercalator, Standard BioTools) in 1.6% PFA at 4 °C overnight.

Labeled samples were acquired using the HELIOS CyTOF system (Standard BioTools) and
FCS files were normalized to EQ Four Element Calibration Beads using the CyTOF software.

645 Immune profiling of serum biomarkers

As previously described (*38*) serum concentrations of cytokines, soluble CD25, chemokines, and growth factors were determined by Luminex ProcartaPlex immunoassays for each marker. List of biomarkers, lower limit of detection and distribution of values within our cohort can be found in **Supplementary Table 3**. Samples values below or equal to the LLOD were replaced by the LLOD.

#### 651 Statistical analysis

652 All statistical analysis in figures comparing cytokines were performed using GraphPad Prism 653 10.1.2. Most graphs were also done using GraphPad Prism, in exception of correlation figures, and machine learning figures that were done using R. Mass cytometry analysis was 654 655 performed using FlowJo. 1-d k-mean clusters were down using the ckmeans.1.dp R packages 656 (Song and Zhong, 2020) and optimal number of cluster evaluated using silhouette method. 657 sPLS-DA was performed using the "mixOmics" package and random forest using the R 658 package "randomForest".). Statistical analysis between groups have been done using either 659 student T test, Mann-Whitney U test or 1-way ANOVA as indicated in figures. All p values 660 below 0.05 were defined as significant.

#### 661 Custom code availability

All custom code used for analysis was written using R or Matlab R2023b. Custom code
example is available on the LCIT github repository (<u>https://github.com/LCIT-</u>
<u>CHUV/ImmunoTox</u>).

665 Data Availability

- 666 The datasets supporting the results of this study are not publicly available. Requests for
- access to the dataset will be granted upon reasonable request to the principal investigator.
- 668 Study data will be managed, stored, shared, and archived according to CHUV standard
- operating procedures to ensure the continued quality, integrity, and utility of the data.

670

671

#### 672 **Discussion**

673 Our comprehensive study examines the immune dynamics of immune-related cytokine 674 release syndrome (irCRS) and reveals distinct patterns across CRS grades. We found that 675 CXCL9, CXCL10 and IFN- $\gamma$  levels increase with CRS severity, suggesting their role as early 676 markers of irCRS onset and progression. This finding underscores the importance of 677 monitoring these markers for early intervention, potentially reducing the severity of irCRS 678 and improving outcomes. When comparing irHLH patients to those with grade 3 irCRS, we 679 found significant elevations in proinflammatory and antitumor cytokines (including IFN- $\gamma$ , 680 IL-6, IL-18, CXCL9, CXCL10, CXCL13, CCL2, CCL3, CCL4, HGF, SCF, and PDGF-B), 681 along with increases in anti-inflammatory cytokines (IL1-RA, IL-10). This cytokine profile 682 suggests a complex inflammatory continuum at the intersection of irCRS severity, irCARS, 683 and oncologic response, highlighting the nuanced immune responses induced by ICI therapy. 684 Our study reveals the simultaneous emergence of irCARS and irCRS during ICI treatment, 685 characterized by increased anti-inflammatory cytokines, particularly IL1-RA and IL-10. This 686 observation highlights a dynamic balance between pro-inflammatory and anti-inflammatory 687 responses that intensifies as CRS progresses. Specifically, we observed a significant increase 688 in IL-10 at grade 4, suggesting its role in amplifying the irCARS response under intense 689 inflammatory condition. We also documented significant correlations between ferritin, d-690 dimer, and Hb and IL-6, illustrating the complex relationship between CRS severity, anemia, 691 and coagulopathy. Furthermore, an increase in IL-1 family cytokines (IL-1 $\beta$ , IL-18, IL-1RA) 692 during ICI therapy suggests inflammasome activation, particularly NLRP3, indicating its 693 substantial influence on the CRS and CARS continuum. NLRP3 inflammasome was reported 694 for its role in processing and releasing pro-inflammatory cytokines, and its significant 695 influence on the inflammatory continuum of CRS and CARS (26).

696 The dominant Th1 response associated with ICI, characterized by significant IFN- $\gamma$ 697 production without substantial involvement of IFN- $\alpha$  or Th17 pathways, suggests a specific 698 immune activation pathway critical for the therapeutic efficacy of ICI. This is further 699 supported by the elevated levels of IL-10, IL1-RA, CXCL9 and CXCL10 in cluster 1 with 700 improved OS highlighting these markers as potential biomarkers of enhanced anti-tumor 701 activity in ICI therapy. Specifically, these inflammatory chemokines bind to the CXCR3 702 receptor and specifically target activated T lymphocytes and natural killer (NK) cells (39-41). 703 A pronounced increase in HGF levels and in IL-10/HGF correlation in patients with severe 704 irAEs (grade 3 and 4) suggests its role as a biomarker for irCARS and for clinical severity. 705 The correlation between HGF levels and irCARS amplification highlights HGF's potential in 706 moderating inflammatory responses, possibly aiding in tissue repair and inflammatory 707 damage mitigation (42). This observation opens avenues for exploring HGF's role in both 708 irCRS and irCARS, particularly in the context of ICI therapy.

709 Our findings underscore the importance of multi-biomarker strategies in refining survival 710 predictions and tailoring therapeutic interventions for irCRS. Notably, we observed 711 contrasting immune patterns between irHLH clusters. Cluster 3, associated with high acute 712 mortality due to irHLH rather than cancer progression, showed elevated inflammatory 713 cytokines (IL-6, IL-8, CXCL8, CXCL13, IL1-RA, HGF, SCF) compared to clusters 1 and 2, 714 which showed better OS and higher levels of CXCL9, CXCL10, IFN- $\gamma$ , and IL-10. This 715 indicates a broader inflammatory response in irHLH and suggests that robust irCARS 716 activation could counterbalance intense inflammation. The distinction between the cytokine 717 profiles in these clusters underscores the complexity of irAEs in irHLH and suggests that 718 more regulated inflammatory responses in clusters 1 and 2 may lead to improved outcomes. 719 Elevated pro-inflammatory cytokines in cluster 3 suggest a cytokine milieu contributing to 720 the severity of irHLH that is distinct from clusters focused on oncologic responses. This

analysis highlights the need for tailored therapeutic strategies based on cluster-specific cytokine patterns and underscores the critical nature of managing the extensive organ involvement and systemic impact seen in severe irHLH cases. Our comprehensive analysis highlights the importance of personalized therapeutic approaches to mitigate adverse outcomes in severe immune-mediated diseases, which is essential to optimize ICI therapy management, especially in patients with severe irAEs such as irHLH.

727

728 The rationale of our study is based on the observed dichotomy between the Lee criteria for 729 CRS grading and the HScore in assessing CRS severity and HLH characteristics. We found 730 significant discrepancies between these criteria, noting cases of high-grade irCRS by Lee 731 criteria with unexpectedly low HScore, and vice versa. This highlights the complexity of 732 categorizing irCRS and irHLH and suggests a continuum between them, ranging from purely 733 biological to mixed clinical manifestations. Our analysis suggests that the HScore alone may 734 inaccurately represent irCRS G3 and irHLH, leading to potential mismanagement based on 735 its sensitivity of approximately 71%. These findings underscore that a high HScore doesn't 736 always warrant aggressive interventions, such as high-dose steroids, typically prompted by 737 high Lee grades. Cases in which a lower HScore is associated with severe CRS challenge the 738 stand-alone utility of the HScore to guide immunosuppressive therapy. Our goal was to 739 identify markers that are more predictive of clinical severity and appropriate initiation of 740 therapy. This approach acknowledges the insights of the HScore, but argues against its sole 741 use for critical decisions, advocating a holistic interpretation that considers the broader 742 clinical context and patient phenotypes. Integrating the Lee criteria and HScore with new 743 biomarkers may lead to more personalized, effective treatment strategies for irCRS and 744 irHLH, using both scores and a comprehensive assessment of clinical and inflammatory 745 markers to improve diagnostic accuracy and interventional guidance.

746 In evaluating 45 biomarkers, our study identified HGF and ferritin as particularly predictive 747 of irHLH versus irCRS G3, with 100% sensitivity and specificity. Biomarkers associated 748 with severe irCRS (grade 4) showed strong discriminatory power such as SCF, IL-6, IL-1RA, 749 CCL2, CXCL9, CXCL13, ASAT, fibrinogen, D-dimer, and prothrombin ratio, while others 750 such as lymphocyte count and hemoglobin were less effective. In particular, CXCL9 stood 751 out for its dual role in distinguishing irHLH from irCRS and predicting the need for treatment 752 intensification with TCZ, underscores the potential for tailored therapeutic strategies. 753 Similarly, HGF, SCF, IL-1RA and others proved valuable in predicting clinical needs such as 754 fluid resuscitation, improving patient management and guiding novel treatments. Similarly, 755 HGF, SCF, IL-1RA, CCL2, IL-18, ferritin, prothrombin ratio, and D-dimer showed dual 756 performance in predicting hemodynamic instability requiring fluid resuscitation and in 757 distinguishing irHLH from irCRS. The potential of these biomarkers to predict critical 758 clinical outcomes, such as hemodynamic instability further underscores their utility in clinical 759 practice.

760

Recent studies are consistent with our findings and showed distinct cytokine profiles in 761 762 irHLH compared to sepsis, with increased levels of CXCL9, CXCL10, and CXCL11 in HLH 763 versus sepsis, while IL-6 was relatively higher in SIRS/sepsis compared to HLH, and IL-10 764 showed no significant difference (43). In addition, we noted a distinct cytokine signature in 765 irHLH, significantly differing from sepsis with elevated IL-10, IL-18, IFN-γ, CCL2, CCL3, 766 HGF, SCF, and IL1-RA, along with ferritin and d-dimer. IL-2R did not distinguish between 767 irHLH and sepsis. Dual inflammatory and biological signatures differentiated the irHLH, 768 sepsis, and grade 3 CRS groups. IL-10, HGH, IL-18, IL1-RA, and SCF were key in irHLH, 769 while leukocytes, IL-7, EGF, PDGF-BB, and GM-CSF were prominent in sepsis. Our data 770 suggest that ferritin, IL-10, EGF and total leukocytes can discriminate between irHLH,

irCRS-3 and sepsis. These biomarkers achieved 100% accuracy in our data, highlighting the
potential of these biomarkers in clinical practice for early diagnosis, patient stratification and
tailored therapies.

774

775 Recent studies have shown that T cell activation profiles can discriminate between hyperinflammatory disorders such as HLH and sepsis, with >7% CD38<sup>high</sup>/HLA-DR+ among 776 777 CD8+ T cells being a key discriminator (44). This was extended to CD38<sup>high</sup>/HLA-DR+CD8+ T cells expressing CD4 (CD4<sup>dim</sup>CD8+ T cells), which correlated with HLH 778 779 severity and levels of CXCL9 and IL-18 (45). Our research explores these immunologic 780 profiles and reveals increased CD38+/HLA-DR+ cell frequencies across multiple T cell 781 subtypes, indicating a specific and robust immune memory response in irCRS, possibly due 782 to prior antigen exposure or the nature of the immune stimulus. This distinct T-cell profile 783 may differentiate irCRS from sepsis and measure the severity of the immune response in 784 patients undergoing ICI therapy.

785 In addition, we found that neutrophils and monocytes in irCRS patients exhibited more 786 CD38, CD11c, and CD62L upregulation than in sepsis, suggesting a different activation 787 profile that could help differentiate irCRS from sepsis. This indicates a different 788 inflammatory and immunoregulatory environment in irCRS, highlighting the potentially 789 unique role of innate immune cells in its pathogenesis. The specific activation of monocytes, 790 which are critical for antigen presentation and cytokine production, highlights their 791 importance in the severity of irCRS and as possible targets for therapeutic intervention or 792 disease monitoring markers.

793

The significant expansion of our patient cohort from three cases in our previous report (15) to the inclusion of twelve patients in this study underscores the growing body of evidence

supporting the efficacy of TCZ in the treatment of CS-refractory high-grade irCRS. This
larger patient cohort not only reaffirms but also strengthens our confidence in the important
therapeutic potential of TCZ.

799 This study has several limitations, including a small cohort size and a limited number of 800 paired samples, which may affect the generalizability of the findings. As a single-center 801 study, it may be subject to selection bias and heterogeneity due to the patient population, 802 differences in disease stage, prior treatments, and comorbidities. This limitation underscores 803 the importance of building larger cohorts to address these confounding factors more 804 accurately. These factors could influence the results of the study. In addition, the lack of 805 validation in independent cohorts limits the reproducibility and robustness of our conclusions. 806 Longitudinal data collection from baseline and during ICI treatment could improve data 807 quality and reliability.

808

809 Despite these limitations, our findings advocate a paradigm shift in the diagnostic approach to 810 immune-related adverse events and propose a multi-biomarker strategy that not only 811 improves diagnostic accuracy but also aids in the prognosis and management of irCRS and 812 irHLH and their distinction from sepsis. This approach promises a significant step toward 813 personalized medicine. It will enable clinicians to predict treatment response and tailor 814 interventions with unprecedented accuracy. Ultimately, this research provides the foundation 815 for a new era in managing irCRS and irHLH characterized by increased diagnostic accuracy, 816 improved patient outcomes, and personalized therapeutic interventions.

817

#### 818 Acknowledgements

This work was supported by the strategic plan of the CHUV. We would like to express our gratitude to all the patients who generously contributed their time and samples for this

821	project. We would like to thank Pr Gérard Waeber and Pr Peter Vollenweider for their help in
822	the clinical care of our patients. We would like to thank Federica Martina for her initial
823	version of the code used in the article. Visual abstract was created with BioRender.com.
824	Author contributions
825	M.O. and D.D. had full access to all data in the study and take responsibility for its integrity
826	and accuracy. MO conceived, designed the study and drafted the manuscript. D.D., G.P., and
827	M.O. analyzed and interpreted the data. D.D., A.S., and M.O. collected the data. S.L., N.M.,
828	H.B., R.D., K.A., N.F., J.D., G.S., L.M., V.M., D.B., A.S., C.S., K.S. and S.P. participated in
829	the clinical treatments. V.J., R.B. and AN analyzed the CyTOF data. D.D. and M.O. prepared
830	the figures. J.T. and Y.W. participated in scientific discussion. The manuscript was reviewed
831	and approved by all authors before submission.
832	
833	Competing interests
834	MO received honoraria and speaker fees from Moderna, Roche and BMS.
835	
836	

- 837
- 838
- 839

#### 840 **Reference**

- J. Haanen *et al.*, Management of toxicities from immunotherapy: ESMO Clinical Practice
   Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 33, 1217-1238 (2022).
- 843 2. F. Martins *et al.*, Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*, (2019).
- 845 3. F. Martins *et al.*, New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. *Lancet Oncol* 20, e54-e64 (2019).
- A. Ceschi, R. Noseda, K. Palin, K. Verhamme, Immune Checkpoint Inhibitor-Related Cytokine
   Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. *Front Pharmacol* 11, 557 (2020).
- 850 5. R. J. Brentjens *et al.*, CD19-targeted T cells rapidly induce molecular remissions in adults with
   851 chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 5, 177ra138 (2013).
- M. L. Davila *et al.*, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* 6, 224ra225 (2014).
- 854 7. U. Winkler *et al.*, Cytokine-release syndrome in patients with B-cell chronic lymphocytic
  855 leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody
  856 (rituximab, IDEC-C2B8). *Blood* 94, 2217-2224 (1999).
- 857 8. C. L. Freeman *et al.*, Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. *Blood* **126**, 2646-2649 (2015).
- M. Cosenza, S. Sacchi, S. Pozzi, Cytokine Release Syndrome Associated with T-Cell-Based
  Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and
  Treatment. *Int J Mol Sci* 22, (2021).
- Y. Kogure, Y. Ishii, M. Oki, Cytokine Release Syndrome with Pseudoprogression in a Patient
  with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. *J Thorac Oncol* 14, e55-e57 (2019).
- 865 11. E. Rassy, T. Assi, J. Rizkallah, J. Kattan, Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. *Immunotherapy* 867 9, 309-311 (2017).
- 868 12. S. H. Tay *et al.*, Cytokine Release Syndrome in Cancer Patients Receiving Immune 869 Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. *Front* 870 *Immunol* 13, 807050 (2022).
- A. Shimabukuro-Vornhagen *et al.*, Cytokine release syndrome. *J Immunother Cancer* 6, 56 (2018).
- K. Bauchmuller *et al.*, Haemophagocytic lymphohistiocytosis in adult critical care. *J Intensive Care Soc* 21, 256-268 (2020).
- 875 15. B. C. Ozdemir *et al.*, Cytokine-directed therapy with tocilizumab for immune checkpoint 876 inhibitor-related hemophagocytic lymphohistiocytosis. *Ann Oncol* **31**, 1775-1778 (2020).
- P. Rajapakse, H. Andanamala, Hemophagocytic Lymphohistiocytosis Secondary to Immune
   Checkpoint Inhibitor Therapy. *World J Oncol* 13, 49-52 (2022).
- M. Sadaat, S. Jang, Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. *J Immunother Cancer* 6, 49 (2018).
- 88118.D. A. Lichtenstein *et al.*, Characterization of HLH-like manifestations as a CRS variant in<br/>patients receiving CD22 CAR T cells. *Blood* **138**, 2469-2484 (2021).
- B. T. Teachey *et al.*, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. *Blood* 121, 5154-5157 (2013).
- R. D. Sandler *et al.*, Diagnosis and Management of Secondary HLH/MAS Following HSCT
  and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within
  EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and
  Transplant Complications Working Party (TCWP). *Front Immunol* **11**, 524 (2020).
- E. Karakike, E. J. Giamarellos-Bourboulis, Macrophage Activation-Like Syndrome: A Distinct
   Entity Leading to Early Death in Sepsis. *Front Immunol* 10, 55 (2019).
- J. T. van Dissel, P. van Langevelde, R. G. Westendorp, K. Kwappenberg, M. Frolich, Anti inflammatory cytokine profile and mortality in febrile patients. *Lancet* **351**, 950-953 (1998).
- C. A. Gogos, E. Drosou, H. P. Bassaris, A. Skoutelis, Pro- versus anti-inflammatory cytokine
  profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J *Infect Dis* 181, 176-180 (2000).

- B97 24. D. Andaluz-Ojeda *et al.*, A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. *Cytokine* **57**, 332-336 (2012).
- J. A. Kellum *et al.*, Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. *Arch Intern Med* 167, 1655-1663 (2007).
- M. Sendler *et al.*, NLRP3 Inflammasome Regulates Development of Systemic Inflammatory
   Response and Compensatory Anti-Inflammatory Response Syndromes in Mice With Acute
   Pancreatitis. *Gastroenterology* **158**, 253-269 e214 (2020).
- 905 27. S. S. Neelapu *et al.*, Chimeric antigen receptor T-cell therapy assessment and management 906 of toxicities. *Nat Rev Clin Oncol* **15**, 47-62 (2018).
- 90728.D. Porter, N. Frey, P. A. Wood, Y. Weng, S. A. Grupp, Grading of cytokine release syndrome908associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11, 35 (2018).
- 909 29. J. H. Park *et al.*, Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic
  910 Leukemia. *N Engl J Med* 378, 449-459 (2018).
- 911 30. N. C. Institue, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (2017).
- 913 31. L. Fardet *et al.*, Development and validation of the HScore, a score for the diagnosis of 914 reactive hemophagocytic syndrome. *Arthritis Rheumatol* **66**, 2613-2620 (2014).
- 815
  82. R. C. Bone *et al.*, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101, 1644-1655 (1992).
- 919 33. M. M. Levy *et al.*, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions
   920 Conference. *Crit Care Med* 31, 1250-1256 (2003).
- 921 34. D. W. Lee *et al.*, Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 124, 188-195 (2014).
- 35. J. I. Henter *et al.*, HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic
  lymphohistiocytosis. *Pediatr Blood Cancer* 48, 124-131 (2007).
- 925 36. C. Knaak *et al.*, Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic 926 reliability of HLH-2004 criteria and HScore. *Crit Care* **24**, 244 (2020).
- A. Noto *et al.*, The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV specific B cell response in viremic infection. *Front Immunol* **13**, 960120 (2022).
- 38. A. Noto *et al.*, CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the
   Magnitude and the Quality of SARS-CoV-2 Humoral Responses. *Viruses* 14, (2022).
- 39. M. T. Chow *et al.*, Intratumoral Activity of the CXCR3 Chemokine System Is Required for the
   Big 200 Efficacy of Anti-PD-1 Therapy. *Immunity* 50, 1498-1512 e1495 (2019).
- W. Feng *et al.*, Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. *Cancer Cell Int* 22, 186 (2022).
- 936 41. N. Karin, CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. *Front Immunol* **11**, 976 (2020).
- M. Perreau *et al.*, The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. *Nat Commun* 12, 4888 (2021).
- H. Lin *et al.*, IFN-gamma signature in the plasma proteome distinguishes pediatric
   hemophagocytic lymphohistiocytosis from sepsis and SIRS. *Blood Adv* 5, 3457-3467 (2021).
- 942 44. V. Chaturvedi *et al.*, T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. *Blood* **137**, 2337-2346 (2021).
- 94445.A. De Matteis *et al.*, Expansion of CD4dimCD8+ T cells characterizes macrophage activation945syndrome and other secondary HLH. *Blood* 140, 262-273 (2022).
- 946



SCF







#### Fig. 4 A

	Hscore	True Diagnosis	Probability of HLH (Hscore)	Ferritin	HGF	Tocilizumab
Predicted irCRS G3						
	52	irCRS G3	0.08	1131	255	No
-	82	irCRS G3	0.49	66	170	Yes
-	94	irCRS G3	1.03	1535	33	Yes
-	138	irCRS G3	13.76	1123	203	Yes
-	146	irCRS G3	20.74	5523	119	No
HScore cutoff for 100% sensitivity in our cohort	154		30.02			
Predicted irHLH						
	162	irHLH	41.26	25861	2000	No
	165	irCRS G3	45.80	4940	188	No
-	175	irHLH	60.93	37714	4194	Yes
-	208	irCRS G3	91.60	3573	55	Yes
-	218	irHLH	94.88	83786	598	Yes
-	226	irHLH	96.45	213600	26600	Yes
-	230	irHLH	97.00	306630	1255	Yes
-	287	irHL H	98.95	705920	1134	Yes





D irl	irHLH vs irCRS-G3 Predictors				ensitivity	Sp	ecificity			
Biomarker	Cutoff	ROC AUC	ROC P value	%	% 95% CI		95% CI	Accuracy	PPV	NPV
Ferritin	< 15692	1	0.0027	100	64.57% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
HGF	< 426.5	1	0.0027	100	64.57% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
SCF	< 13.00	0.9881	0.0034	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
CCL4	< 158.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
IL-10	< 6.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
IL-18	< 169.0	0.9762	0.0043	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
aPTT	< 32.50	0.9714	0.0074	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100
IL-1RA	< 12251	0.9524	0.0066	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
CCL2	< 97.50	0.9286	0.0101	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
D-Dimer	< 12708	0.9143	0.0185	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100
PDGF-B	< 25.50	0.9048	0.0152	85.71	48.69% to 99.27%	100	60.97% to 100.0%	92.31	85.71	100.00
Prothrombin Ratio	> 65.00	0.9048	0.0152	100	64.57% to 100.0%	66.67	30.00% to 94.08%	84.62	100.00	77.78
ASAT	< 297.5	0.881	0.0223	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CCL11	< 25.50	0.881	0.0223	71.43	35.89% to 94.92%	100	60.97% to 100.0%	84.62	75.00	100.00
CXCL9	< 357.5	0.881	0.0223	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
LIF	< 6.500	0.881	0.0223	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
Fibrinogen	> 1.450	0.8571	0.0321	100	64.57% to 100.0%	83.33	43.65% to 99.15%	92.31	100.00	87.50
CCL3	< 8.50	0.8452	0.0383	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CXCL10	< 209.5	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
CXCL13	< 357.0	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
IFNγ	< 16.50	0.8333	0.0455	57.14	25.05% to 84.18%	100	60.97% to 100.0%	76.92	66.67	100.00
IL-6	< 42.65	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
Platelets	> 79.00	0.8333	0.0455	85.71	48.69% to 99.27%	83.33	43.65% to 99.15%	84.62	83.33	85.71
Hscore	< 154.0	0.9286	0.0101	71.43	35.89% to 94.92%	100	60.97% to 100.0%	84.62	75.00	100.00

Е	Tocilizumab Escalation Predictors				Se	nsitivity	Sp	ecificity			
	Biomarker	Cutoff	ROC AUC	ROC P value	%	95% CI	%	95% CI	Accuracy	PPV	NPV
	CXCL9	< 80.00	0.8889	0.0308	75	30.06% to 98.72%	100	70.09% to 100.0%	92.31	90.00	100.00
	Total Bilirubine	< 11.00	0.9167	0.0206	100	51.01% to 100.0%	77.78	45.26% to 96.05%	84.62	100.00	66.67
	Hscore	< 170.0	0.75	0.1649	100	51.01% to 100.0%	66.67	35.42% to 87.94%	76.92	100.00	57.14

Fig. 5

A Seps	sis vs irCRS-	-G3 & irHLH Pred	dictors	Se	nsitivity	Sp	ecificity			
Biomarker	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI	Accuracy	PPV	NPV
Total Leucocytes	0.9808	0.0046	> 8.900	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
Neutrophils	0.9744	0.0128	> 5.925	100	43.85% to 100.0%	92.31	66.69% to 99.61%	93.75	75.00	100
IL-7	0.9615	0.0066	> 4.000	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
EGF	0.9423	0.0092	> 62.50	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
Fibrinogen	0.9423	0.0092	> 5.850	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
CXCL10	0.9327	0.0108	< 75.00	100	51.01% to 100.0%	92.31	66.69% to 99.61%	94.12	80.00	100
GM-CSF	0.9038	0.0174	> 19.00	100	51.01% to 100.0%	76.92	49.74% to 91.82%	82.35	57.14	100
Alkaline Phosphatase	0.8974	0.037	> 261.5	100	43.85% to 100.0%	69.23	42.37% to 87.32%	75.00	42.86	90
Gamma-GT	0.8974	0.037	> 250.0	100	43.85% to 100.0%	76.92	49.74% to 91.82%	81.25	50.00	100
ALAT	0.8654	0.0315	< 97.00	100	51.01% to 100.0%	76.92	49.74% to 91.82%	82.35	57.14	100
IL-6	0.8462	0.0415	> 203.0	100	51.01% to 100.0%	84.62	57.77% to 97.27%	88.24	66.67	100
3	Soncie ve ir(	re	Se	neitivity	Sr	ecificity				

Sepsis vs ir ChS-GS Fredicions				Sensitivity			echicity			
Biomarker	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI	Accuracy	PPV	NPV
Total Leucocytes	1	0.0082	> 8.250	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
Neutrophils	1	0.0167	> 5.925	100	43.85% to 100.0%	100	64.57% to 100.0%	100	100	100
IL-6	1	0.0082	> 203.0	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
EGF	1	0.0082	> 53.50	100	51.01% to 100.0%	100	64.57% to 100.0%	100	100	100
Alkaline Phosphatase	0.9524	0.0304	> 249.0	100	43.85% to 100.0%	85.71	48.69% to 99.27%	90	75	100
IL-7	0.9286	0.0233	> 3.000	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
GM-CSF	0.9286	0.0233	> 19.00	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
Fibrinogen	0.8929	0.0376	> 5.600	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
IL-15	0.8929	0.0376	> 5.500	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100
CXCL10	0.875	0.0472	< 75.00	100	51.01% to 100.0%	85.71	48.69% to 99.27%	90.91	80	100



Ferritin:										
irHLH vs irCRS-G	3 + Sepsis									
Cutoff	< 23221									
Sensitivity	100%									
Specificity	100%									
ROC Area	1									
ROC P value	0.0009									





#### **Supplementary Figure 1**



Supplementary Fig. vas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pe All rights reserved. No reuse allowed without permission.





SM IgG2+ 1.00 0.80 SM IgG3+ ICRS Low grade Baseline ICRS HUNDRAGE

0.81

0.42

0.56

0.94

0.81

0.82

0.69

0.46

1.06

0.62

1.08

1.00

1.00

1.00

1.00

1.00

Double-Negative B cells

Unswitched Memory B cells

Switched Memory B cells

SM IgA1-IgA2-/IgM+

SM IgA1+

SM IgA2+

SM lgG1+

8

6

4

2

6

4

2

0

8

6

4

2

8

6

4

2

0

8

6

4

2

Cluster eG4

4 1

0 0

0



в

A Immunosupressive treatment							atments					
			Probability	Respiratory	Fluid		Fresh Frozen	n Corticosteroids			Tocilizumat	Number
ID	Diagnosis	HScore	of irHLH	Distress	Resuscitation	Vasopressors	Plasma	HDS	Highest Dose	TCZ	Dose	of TRT
1	irHLH	162	41.4	Yes	Yes	Yes	No	Yes	2 mg/kg	No		0
2	irHLH	175	61.3	Yes	Yes	Yes	Yes	Yes	2 mg/kg	Yes	8 mg/kg	1
3	irHLH	218	95.8	No	No	No	Yes	Yes	1 mg/kg	Yes	8 mg/kg	1
4	irHLH	226	97.4	Yes	Yes	Yes	Yes	Yes	10 mg/kg	Yes	8 mg/kg	1
5	irHLH	230	98.0	Yes	Yes	No	Yes	Yes	10 mg/kg	Yes	8 mg/kg	1
6	irHLH	287	99.9	Yes	Yes	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
7	irCRS Grade 3	138	13.8	No	No	No	No	Yes	5 mg/kg	Yes	8 mg/kg	2
8	irCRS Grade 3	208	92.5	No	No	No	Yes	Yes	N/A	Yes	8 mg/kg	1
9	irCRS Grade 3	94	1.0	Yes	No	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
10	irCRS Grade 3	165	46.0	Yes	No	No	No	No		No		0
11	irCRS Grade 3	82	0.5	No	No	No	No	Yes	1 mg/kg	Yes	8 mg/kg	2
12	irCRS Grade 3	52	0.1	No	No	No	No	Yes	1 mg/kg	No		0
13	irCRS Grade 3	146	20.8	No	No	No	No	No		No		0
	n (%) in irHLH			5/6 (83%)	5/6 (83%)	3/6 (50%)	4/6 (67%)	6/6 (100%)		5/6 (83%)		
	n (%) in irCRS			2/7 (29%)	0/6 (0%)	0/6 (0%)	1/6 (17%)	5/7 (71%)		4/7 (29%)		

в	- Iuid Resusci	tation Predictor	5	Se	ensitivity	Sp	ecificity			
Biomarker	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI	Accuracy	PPV	NPV
HGF	1	0.0034	< 866.0	100	67.56% to 100.0%	100	56.55% to 100.0%	100.00	100.00	100.00
SCF	1	0.0034	< 18.50	100	67.56% to 100.0%	100	56.55% to 100.0%	100.00	100.00	100.00
aPTT	1	0.0066	< 43.00	100	67.56% to 100.0%	100	51.01% to 100.0%	100.00	100.00	100.00
Prothrombin Ratio	0.975	0.0054	> 65.00	100	67.56% to 100.0%	80	37.55% to 98.97%	92.31	100.00	88.89
CXCL13	0.95	0.0084	< 357.0	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
Ferritin	0.95	0.0084	< 15692	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
IL-1RA	0.925	0.0128	< 18130	100	67.56% to 100.0%	80	37.55% to 98.97%	92.31	100.00	88.89
PDGF-B	0.925	0.0128	< 29.50	87.5	52.91% to 99.36%	100	56.55% to 100.0%	92.31	83.33	100.00
D-Dimers	0.9143	0.0185	< 12708	85.71	48.69% to 99.27%	100	56.55% to 100.0%	91.67	83.33	100.00
CCL4	0.9	0.0192	< 158.0	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
IL-10	0.875	0.0281	< 6.000	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
AST	0.875	0.0281	< 373.5	87.5	52.91% to 99.36%	80	37.55% to 98.97%	84.62	80.00	87.50
IL-18	0.85	0.0404	< 169.0	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
CCL2	0.85	0.0404	< 97.50	75	40.93% to 95.56%	100	56.55% to 100.0%	84.62	71.43	100.00
Hscore	0.875	0.0281	< 154.0	62.5	30.57% to 86.32%	100	56.55% to 100.0%	76.92	62.50	100.00

C Re	spiratory Di	stress Predict	ors	S	ensitivity	Sp	pecificity			
Biomarker	Cutoff	ROC AUC	ROC P value	%	95% CI	%	95% CI	Accuracy	PPV	NPV
aPTT	< 35.00	0.9667	0.0106	100	56.55% to 100.0%	83.33	43.65% to 99.15%	90.91	100.00	83.33
Platelets	> 191.5	0.9429	0.0118	80	37.55% to 98.97%	100	64.57% to 100.0%	91.67	87.50	100.00
Prothrombine Ratio	> 82.50	0.9429	0.0118	80	37.55% to 98.97%	100	64.57% to 100.0%	91.67	87.50	100.00
D-Dimer	< 12708	0.9429	0.0118	100	56.55% to 100.0%	85.71	48.69% to 99.27%	91.67	100.00	83.33
CCL2	< 97.50	0.9286	0.0149	100	56.55% to 100.0%	85.71	48.69% to 99.27%	91.67	100.00	83.33
Ferritine	< 15692	0.9143	0.0185	100	56.55% to 100.0%	71.43	35.89% to 94.92%	83.33	100.00	71.43
CRP	< 82.00	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
Hemoglobin	> 98.50	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
IL-18	< 93.00	0.8857	0.0284	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00
Hscore	< 154.0	0.8286	0.0618	80	37.55% to 98.97%	85.71	48.69% to 99.27%	83.33	85.71	80.00



Α				0	В				 _ 0
CD4+ -	1.00	0.87	0.89	°	CD8+ -	1.00	1.22	1.35	l°
CD4 Naive -	1.00	0.55	1.04		CD8 Naive -	1.00	0.44	0.78	
CD4 CM -	1.00	1.14	0.95		CD8 CM -	1.00	0.79	0.71	
CD4 EM -	1.00	0.61	0.72		CD8 EM -	1.00	1.04	0.79	
CD4 TM -	1.00	0.85	1.41		CD8 TM -	1.00	1.17	1.68	
CD4 Memory -	1.00	1.21	0.98	6	CD8 TEMRA -	1.00	0.42	0.36	 6
CD4 Memory CCR4+ -	1.00	0.93	1.29		CD8 Memory -	1.00	1.13	1.05	
CD4 Memory CCR6+ -	1.00	0.62	0.61		CD8 Memory CCR4+ -	1.00	0.39	1.64	
CD4 Memory CD25+ -	1.00	0.94	1.18		CD8 Memory CCR6+ -	1.00	0.14	0.25	
CD4 Memory CD38+ -	1.00	1.98	7.92		CD8 Memory CD25+ -	1.00	0.97	1.75	
CD4 Memory CD69+ -	1.00	0.86	2.13	4	CD8 Memory CD38+ -	1.00	3.25	11.46	4
CD4 Memory CXCR3+ -	1.00	0.92	0.98		CD8 Memory CD69+ -	1.00	0.40	2.92	
CD4 Memory CXCR5+ -	1.00	0.98	0.91		CD8 Memory CXCR3+ -	1.00	0.81	0.84	
CD4 Memory HLA-DR+ -	1.00	0.99	2.75		CD8 Memory CXCR5+ -	1.00	1.13	0.61	
Th1 -	1.00	1.15	1.05		CD8 Memory HLA-DR+	1.00	2.91	3.93	
Th17 –	1.00	0.96	1.04		CD8+ HLA-DR+/CD38+ -	1.00	10.47	19.98	 2
Th2 -	1.00	1.48	1.00	- 2	CD8 Naive HLA-DR+/CD38+ -	1.00	9.29	16.87	
CD4+ HLA-DR/CD38+ -	1.00	2.02	17.23		CD8 CM HLA-DR+/CD38+ -	1.00	7.46	12.24	
CD4 Naive HLA-DR+/CD38+ -	1.00	0.65	2.43		CD8 TM HLA-DR+/CD38+ -	1.00	3.39	6.01	
CD4 CM HLA-DR+/CD38+ -	1.00	1.96	12.10		CD8 EM HLA-DR+/CD38+ -	1.00	5.46	6.81	
CD4 TM HLA-DR+/CD38+ -	1.00	2.28	8.31		CD8 TEMRA HLA-DR+/CD38+	1.00	5.88	9.59	0
CD4 EM HLA-DR+/CD38+	1.00	3.08	7.39	0	D				•
с				8	CD16 NK cell	1.00	0.56	1.02	l°
CL monocytes -	1.00	0.91	0.88		CD56 NK cell -	1.00	1.38	1.58	
CL CD11c+ -	1.00	0.33	0.99		NKT cell -	1.00	0.92	0.91	5
CL CD1c+ -	1.00	0.15	0.41		TCR γδ+ -	1.00	0.92	0.61	6
CL CD38+ -	1.00	0.88	7.54		F				Ũ
	1.00	0.19	2.38	6	CD141+ DC -	1.00	0.47	0.51	
	1.00	1.00	1.20		conventional mDC -	1.00	0.17	0.18	 4
ITM CD11ct -	1.00	0.65	0.02		pDC -	1.00	0.05	0.40	 2
	1.00	0.05	0.02		-				• 0
ITM CD38+ -	1.00	0.57	17.08	4	F Noutrophilo	1.00	1.01	0.07	8
ITM CXCR3+ -	1.00	0.48	0.95		Neutrophils CD11c	1.00	0.60	1.22	
ITM HLA-DR+ -	1.00	0.75	0.88		Neutrophils CD38+	1.00	1 19	3.04	
NCL monocytes -	1.00	1.14	0.88		Neutrophils CD62L + -	1.00	0.57	1.30	 6
NCL CD11c+ -	1.00	0.37	0.87	2	Mature Neutrophils -	1.00	0.47	0.53	
NCL CD1c+ -	1.00	0.21	1.17		Mature CD11c -	1.00	1.02	1.38	
NCL CD38+ -	1.00	0.15	4.66		Mature CD38+ -	1.00	1.39	3.17	 4
NCL CXCR3+ -	1.00	0.35	0.81		Mature CD62L+ -	1.00	0.70	1.38	
NCL HLA-DR+ -	1.00	0.45	1.13	0	Immature Neutrophils -	1.00	2.24	2.17	
	e	eis	8	0	Immature CD11c -	1.00	1.56	3.55	2
~	aselli	Ser	ndiar		Immature CD38+ -	1.00	1.13	3.71	
X	,	S.Y	6		Immature CD62L+ -	1.00	0.62	1.61	0
		WCP2			6				U
					Plasmocytes -	1.00	1 58	1 97	8

Mature CD62L+ -	1.00	0.70	1.38
Immature Neutrophils -	1.00	2.24	2.17
Immature CD11c -	1.00	1.56	3.55
Immature CD38+ -	1.00	1.13	3.71
Immature CD62L+ -	1.00	0.62	1.61
à			
Plasmocytes -	1.00	1.58	1.97
naive B cells -	1.00	0.93	1.25
Double-Negative B cells -	1.00	1.03	0.82
Unswitched Memory B cells -	1.00	1.17	0.69
Switched Memory B cells -	1.00	1.13	0.46
SM IgA1+ -	1.00	1.15	1.06
SM IgA1-IgA2-/IgM+ -	1.00	0.48	1.02
SM IgA2+ -	1.00	0.99	0.62
SM IgG1+ -	1.00	0.63	1.08
SM IgG2+ -	1.00	0.97	0.80
SM IgG3+ -	1.00	1.13	1.11
a	aseline	Sepsis	ngrade
×	,	-RS HI	2
		.{C1	







D





Biomarker	% as main node of trees			
Ferritin	75%			
HGF	10%			
EGF	8%			
Leucocytes count	4%			
PDGF-B	3%			

Supplementary Figure 9: Grating Strategy wire provide blood



### CD38+ HLA-DR+ in T cells



## (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary Figure 9<sup>AI</sup>("contrinued): Gratting Strategy from whole blood



#### 

106Cd	CCR6
111Cd	CD141
112Cd	CD69
113ln	CD8
115ln	CD4
116Cd	lgA2
141Pr	CD45
142Nd	CD19
143Nd	ICOS
144Nd	lgG3
145Nd	CD31
146Nd	lgD
147Sm	CD7
148Nd	lgA1
149Sm	CD127
150Nd	lgG1
151Eu	CD123
152Sm	CD21
153Eu	CD62L
154Sm	CD3
155Gd	CD27
156Gd	ΤCRγδ
158Gd	CD10
159Tb	CCR7
160Gd	CD14
161Dy	CD1c
162Dy	CD11c
163Dy	CXCR3
164Dy	CXCR5
165Ho	CD45RO
166Er	CD24
167Er	CD38
168Er	CD66b
169Tm	CD25
170Er	CD45RA
171Yb	CD20
172Yb	lgM
173Yb	ΤϹℝαβ
174Yb	HLADR
175Lu	PD1
176Yb	CD56
191lr	DNA1
193Ir	DNA2
194Pt	CCR4
198Pt	lgG2
209Bi	CD16

Cohort description		n = 35	% within cohort
Age			
	Median (range)	57 (60)	
Sex			
	Male	23	66%
	Female	12	34%
<u>Median times (days)</u>			
	Median time of onset	58	
	Median time of follow up	896	
Tumor type			
	Melanoma	17	49%
	Lung	11	31%
	Urological	3	9%
	Others	4	11%
irAE type			
	irCRS	28	80%
	among irCRS : irHLH	9	32% of CRS
Sepsis during ICI			
	Sepsis during ICI	7	20%
irCBS Clinical grade			
Low grade [43%]	1	2	7%
	2	10	36%
High grade [57%]	3		29%
	4	8	29%
Immune Checkpoint Inhibitors (ICI)		0	20,0
anti PD-I 1	Atezolimumah	2	6%
	Durvalumah	1	3%
anti PD-1	Pembrolizumah	8	23%
	Nivolumah	3	9%
anti PD-1 + anti CTI A-4	Inilimumab + Nivolumab	21	60%
		21	0070
	la lla company de la Nili de la company	0	1000/
	Ipilimumab + Nivolumab	2	100%
Grade 2		/	70%
	Periodizumab	2	20%
Crada 2	burvalumab	- 1	10%
Grade 3		/	00%
Crada 4			13%
Grade 4		5	63%
	Nivelumen	2	20%
	Nivolumao	1	13%
Sepsis during ICI	Pembrolizumab	3	43%
		2	29%
	Alezoiimumab	2	29%
Immunosuppressive treatment (IS) for irCRS			
	Corticosteroids (CS)	3	11%
	CS + anti-IL6R (Tocilizumat	o) 13	46%
	None	12	43%

Patients Reciving Tocilizumab	n	(N=12)	%
Sex			
	Male	6	50
	Female	6	50
Age			
	Median (Mean)	46 (48)	
Mortality related to irCRS			
	7 days	0	0.00
	30 days	0	0.00
Clinical Grading			
	irCRS Grade 3	5	41.67
	irCRS Grade 4	7	58.33
 irHLH			
	irHLH within Grade 3	1	20.00
	irHLH within Grade 4	7	100.00
Severity factors			
	Acute respiratory failure	5	41.67
	Acute Kidney Injury	7	58.33
	Acute Liver failure	2	16.67
	Admission in Intensive or Intermediate Care	ə 5	41.67
	DIC	6	50.00
	Fluid resuscitation	5	41.67
	Vasopressors	2	16.67
	High dose of steroids (HDS)	12	100.00
Mortality related to irHLH			
	7 days	0	0.00
	30 days	0	0.00
irHLH response			
	Complete Resolution	12	100.00
Oncological response 3 months after TCZ	•		
	Complete Response (CR)	3	25.00
	Stable Disease (SD)	2	16.67
	Partial Response (PR)	0	0.00
	Progressive Disease (PD)	6	50.00
	Not Assessed	1	8.33
Oncological response 6 months after TCZ			
	Complete Response (CR)	4	33.33
	Stable Disease (SD)	2	16.67
	Partial Response (PR)	0	0.00
	Progressive Disease (PD)	3	25.00
	Not Assessed	3	25.00

#### Hscore + CRP: HR and P values

Clusters	HR	95% CI of ratio	P value	Significance
Cluster D1 vs Cluster D2	2.642	0.2940 to 23.75	0.3072	ns
Cluster D1 vs Cluster D3	1.419	0.3232 to 6.232	0.6429	ns
Cluster D1 vs Cluster D4	1.603	0.2137 to 12.02	0.6332	ns
Cluster D2 vs Cluster D3	4.788	1.153 to 19.89	0.0323	•
Cluster D2 vs Cluster D4	4.693	0.3573 to 61.65	0.085	ns
Cluster D3 vs Cluster D4	1.319	0.2346 to 7.419	0.7325	ns

#### Hscore + CRP + Creatinin: HR and P values

Clusters	HR	95% CI of ratio	P value	Significance
Cluster F1 vs Cluster F2	9.442	0.2762 to 322.7	0.002	**
Cluster F1 vs Cluster F3	9.535	0.2201 to 413.1	0.0004	***
Cluster F1 vs Cluster F4	3.068	0.3150 to 29.87	0.2072	ns
Cluster F2 vs Cluster F3	3.35	0.7693 to 14.59	0.0767	ns
Cluster F2 vs Cluster F4	4.496	0.3293 to 61.38	0.068	ns
Cluster F3 vs Cluster F4	1.504	0.2440 to 9.267	0.6224	ns

		Cluster 1 (n=7)	Cluster 2 (n=18)	Cluster 3 (n=3)
Grading irCRS/irHLH				
	1	0	2	0
	2	0	9	0
	3	4	4	0
	4	3	2	3
	irHLH Patients	4	2	3
Cancer type				
	Breast	0	1	0
	Digistive	0	2	0
	Lung	0	7	2
	Melanoma	7	8	0
	Genitourinary	0	0	1
Treatment				
	TCZ + GC	6	5	2
	GC	1	1	1
	No Immunosupressors	s 0	11	0

irHLH	vs irCRS-G3	& Sepsis Predi	ictors	Se	nsitivity	Sp	pecificity			
Biomarker	ROC AUC	ROC P value	Cutoff	%	95% CI	%	95% CI	Accuracy	PPV	NPV
Ferritin	1	0.0009	< 23221	100	74.12% to 100.0%	100	60.97% to 100.0%	100.00	100.00	100.00
CCL4	0.9848	0.0013	< 164.0	90.91	62.26% to 99.53%	100	60.97% to 100.0%	94.12	85.71	100.00
HGF	0.9848	0.0013	< 592.5	90.91	62.26% to 99.53%	100	60.97% to 100.0%	94.12	85.71	100.00
IL-1RA	0.9697	0.0018	< 12251	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
IL-10	0.9697	0.0018	< 25.00	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
IL-18	0.9697	0.0018	< 391.0	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
SCF	0.947	0.003	< 21.00	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
aPTT	0.93	0.0085	< 43.85	100	72.25% to 100.0%	80	37.55% to 98.97%	93.33	100.00	90.91
CCL2	0.9242	0.0049	< 211.5	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
D-Dimers	0.92	0.0101	< 12708	80	49.02% to 96.45%	100	56.55% to 100.0%	86.67	71.43	100.00
Fibrinogen	0.9091	0.0067	> 1.450	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
CXCL9	0.9091	0.0067	< 357.5	100	74.12% to 100.0%	83.33	43.65% to 99.15%	94.12	100.00	91.67
Prothrombin Ratio	0.8939	0.009	> 65.00	100	74.12% to 100.0%	66.67	30.00% to 94.08%	88.24	100.00	84.62
CXCL10	0.8939	0.009	< 196.5	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
CCL3	0.8712	0.0138	< 8.500	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
IFN-γ	0.8636	0.0159	< 16.50	63.64	35.38% to 84.83%	100	60.97% to 100.0%	76.47	60.00	100.00
Platelets	0.8485	0.0208	> 79.00	81.82	52.30% to 96.77%	83.33	43.65% to 99.15%	82.35	71.43	90.00
CXCL13	0.8333	0.027	< 440.0	90.91	62.26% to 99.53%	83.33	43.65% to 99.15%	88.24	83.33	90.91
CCL11	0.803	0.0444	< 25.50	63.64	35.38% to 84.83%	100	60.97% to 100.0%	76.47	60.00	100.00